Clinical trialNCT01750281CompletedPhase 2Interventional

Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.

SponsorAstraZenecaEnrollment212Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Gabriella Mariani, MD
AstraZeneca UK, MSD
Study Chair
clinicaltrials.gov ↗
Jean-Charles Soria, MD
Institut de Cancerology Gustave Roussy, France
Principal Investigator
clinicaltrials.gov ↗
Pasi Janne, MD
Dana-Farber Cancer Institute, USA
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

68 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Brazil

Research Site
Barretos, Brazil
Research Site
Brasília, Brazil
Research Site
Ijuí, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Santo André, Brazil
Research Site
São José do Rio Preto, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil

Bulgaria

Research Site
Plovdiv, Bulgaria
Research Site
Plovdiv, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Varna, Bulgaria
Research Site
Vratsa, Bulgaria

France

Research Site
Brest, France
Research Site
Caen, France
Research Site
Clermont-Ferrand, France
Research Site
Lille, France
Research Site
Pierre-Bénite, France
Research Site
Villejuif, France

Germany

Research Site
Essen, Germany
Research Site
Esslingen am Neckar, Germany
Research Site
Großhansdorf, Germany
Research Site
Karlsruhe, Germany
Research Site
Löwenstein, Germany
Research Site
Moers, Germany
Research Site
Wiesbaden, Germany
Research Site
Würzburg, Germany

Hungary

Research Site
Budapest, Hungary
Research Site
Budapest, Hungary
Research Site
Budapest, Hungary
Research Site
Edelény, Hungary
Research Site
Győr, Hungary
Research Site
Kaposvár, Hungary
Research Site
Miskolc, Hungary

28 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Docetaxel →PlaceboSelumetinib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 18 Dec 2012
Primary completion: 27 Jan 2016
Completion: 31 Oct 2022
Last update posted: 24 Oct 2023
Registered enrollment: 212
Registry id: NCT01750281

Cross-registrations

EU-CTR / CTIS (EudraCT)2012-003622-25

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.